missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Beschreibung
- Tamoxifen has been used to facilitate the recombination of ect2flox allele in mouse organs
- It has also been used to study its effect on lipopolysaccharide (LPS)-induced microglial activation
Spezifikation
Spezifikation
| Melting Point | 96°C to 100°C |
| Color | White |
| Linear Formula | C26H29NO |
| Quantity | 1 g |
| Synonym | tamoxifen, trans-tamoxifen, crisafeno, soltamox, tamoxifene, diemon, tamoxifeno, tamoxifenum, citofen, istubol |
| Solubility Information | Practically insoluble in water (< 0.01% at 20°C); soluble in methanol, ethanol, 2-propanol, propylene glycol, chloroform (50mg/mL - clear, colorless to faint yellow solution) or DMSO. |
| IUPAC Name | 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine |
| Formula Weight | 371.5 |
| Physical Form | Powder |
| Chemical Name or Material | TAMOXIFEN |
Sicherheit und Handhabung
Produktidentifikator
- Tamoxifen, Free Base
- Danger
- Carcinogenicity Category 1A
- Reproductive toxicity Category 1A
- H350-May cause cancer.
- H360-May damage fertility or the unborn child.
- H362-May cause harm to breast-fed children.
- P101-If medical advice is needed, have product container or label at hand.
- P102-Keep out of reach of children.
- P103-Read label before use.
- P263-Avoid contact during pregnancy/while nursing.
- P260-Do not breathe dust/fume/gas/mist/vapours/spray.
- P280-Wear protective gloves/protective clothing/eye protection/face protection.
- P308+P313-IF exposed or concerned: Get medical advice/attention.
- P405-Store locked up.
- P501-Dispose of contents/container to .
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?